Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861793 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
A Phase 1 study, sponsored by Mural Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT03861793 is a Phase 1 study that has completed, run by Mural Oncology. The registered enrollment target is 116 participants.
The verdict
NCT03861793, a Phase 1 study, has completed, sponsored by Mural Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL ALKS 4230
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861793
The ClinicalTrials.gov registry entry for NCT03861793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mural Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03861793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03861793 about?
NCT03861793 is a clinical study titled "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)". This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
What is the current status of trial NCT03861793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2019-02-26. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT03861793?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), ALKS 4230 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03861793?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.